Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment by Wiegman, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/155263
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
REVIEW
Prevention
Familial hypercholesterolaemia in children and
adolescents: gaining decades of life by optimizing
detection and treatment
Albert Wiegman1†*, Samuel S. Gidding2†, Gerald F. Watts3, M. John Chapman4,5,
Henry N. Ginsberg6,7, Marina Cuchel8, Leiv Ose9,10, Maurizio Averna11,
Catherine Boileau12,13,14, Jan Bore´n15,16, Eric Bruckert17, Alberico L. Catapano18,19,
Joep C. Defesche20, Olivier S. Descamps21, Robert A. Hegele22, G. Kees Hovingh20,
Steve E. Humphries23, Petri T. Kovanen24, Jan Albert Kuivenhoven25, Luis Masana26,
Børge G. Nordestgaard27,28, Pa¨ivi Pajukanta29, Klaus G. Parhofer30, Frederick J. Raal31,
Kausik K. Ray32, Raul D. Santos33,34, Anton F.H. Stalenhoef35, Elisabeth Steinhagen-
Thiessen36,37, Erik S. Stroes20, Marja-Riitta Taskinen38, Anne Tybjærg-Hansen39,40, and
Olov Wiklund41,42, for the European Atherosclerosis Society Consensus Panel‡
1Department of Paediatrics, Academic Medical Center, University of Amsterdam, The Netherlands; 2Nemours Cardiac Center, A. I. DuPont Hospital for Children, Wilmington, DE, USA;
3School of Medicine and Pharmacology, Royal Perth Hospital Unit, The University of Western Australia, Western Australia, Australia; 4Pierre and Marie Curie University, Paris, France;
5National Institute for Health and Medical Research (INSERM), Pitie´-Salpeˆtrie`re University Hospital, Paris, France; 6Columbia University College of Physicians and Surgeons, New York,
NY, USA; 7Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, USA; 8Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA, USA; 9Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; 10Lipid Clinic, Oslo University Hospital, Oslo, Norway;
11Department of Internal Medicine, University of Palermo, Italy; 12Diderot Medical School, University Paris 7, Paris, France; 13Genetics Department, Bichat University Hospital, Paris,
France; 14INSERM U698, Paris, France; 15Department of Medicine, Sahlgrenska Academy, Go¨teborg University, Gothenburg, Sweden; 16Wallenberg Laboratory for Cardiovascular
Research, Gothenburg, Sweden; 17Department of Endocrinology and Prevention of Cardiovascular Disease, University Hospital Pitie´-Salpeˆtrie`re, Paris, France; 18Department of
Pharmacology, Faculty of Pharmacy, University of Milano, Milan, Italy; 19Multimedica IRCSS, Milan, Italy; 20Department of Vascular Medicine, Academic Medical Center, University of
Amsterdam, The Netherlands; 21Centre Hospitalier Jolimont-Lobbes, Nivelles-Tubize, Belgium; 22Robarts Research Institute, University of Western Ontario, London, ON, Canada;
23Centre for Cardiovascular Genetics, University College London, Institute of Cardiovascular Sciences, London, UK; 24Wihuri Research Institute, Helsinki, Finland; 25Department of
Pediatrics, Section Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 26Vascular Medicine and Metabolic Unit,
Department of Medicine and Surgery, University Rovira and Virgili, Reus-Tarragona, Spain; 27Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital,
Herlev, Denmark; 28Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 29Department of Human Genetics, Center for Metabolic Disease
Prevention, University of California, Los Angeles, USA; 30Department of Endocrinology and Metabolism, University of Munich, Munich, Germany; 31Carbohydrate & Lipid Metabolism
Research Unit; and Division of Endocrinology & Metabolism, University of the Witwatersrand, Johannesburg, South Africa; 32Department of Primary Care and Public Health, School of
Public Health, Imperial College, London, UK; 33Lipid Clinic of the Heart Institute (InCor), University of Sa˜o Paulo, Sa˜o Paulo, Brazil; 34Department of Cardiology, University of Sa˜o Paulo
Medical School, Sa˜o Paulo, Brazil; 35Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; 36Evangelisches Geriatriezentrum Berlin gGmbH (EGZB),
Berlin, Germany; 37Charite´ – Universita¨tsmedizin, Berlin, Germany; 38Research Programs Unit, Diabetes & Obesity, University of Helsinki and Heart & Lung Centre, Helsinki University
Hospital, Helsinki, Finland; 39Department of Clinical Biochemistry, Section for Molecular Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 40Faculty of
Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 41Department of Experimental and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden; and 42Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
Received 16 February 2015; revised 8 April 2015; accepted 19 April 2015; online publish-ahead-of-print 25 May 2015
Familial hypercholesterolaemia (FH) is a common genetic cause of premature coronary heart disease (CHD). Globally, one baby is born with FH
every minute. If diagnosed and treated early in childhood, individuals with FH can have normal life expectancy. This consensus paper aims to
improve awareness of the need for early detection and management of FH children. Familial hypercholesterolaemia is diagnosed either on pheno-
typic criteria, i.e. anelevated low-density lipoprotein cholesterol (LDL-C) levelplus a family historyof elevated LDL-C,prematurecoronaryartery
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disease and/or genetic diagnosis, or positive genetic testing. Childhood is the optimal period for discrimination between FH and non-FH using
LDL-C screening. An LDL-C ≥5 mmol/L (190 mg/dL), or an LDL-C ≥4 mmol/L (160 mg/dL) with family history of premature CHD and/or
high baseline cholesterol in one parent, make the phenotypic diagnosis. If a parent has a genetic defect, the LDL-C cut-off for the child is
≥3.5 mmol/L (130 mg/dL). We recommend cascade screening of families using a combined phenotypic and genotypic strategy. In children,
testing is recommended from age 5 years, or earlier if homozygous FH is suspected. A healthy lifestyle and statin treatment (from age 8 to
10 years) are the cornerstones of management of heterozygous FH. Target LDL-C is ,3.5 mmol/L (130 mg/dL) if .10 years, or ideally 50%
reduction from baseline if 8–10 years, especially with very high LDL-C, elevated lipoprotein(a), a family history of premature CHD or other
cardiovascular risk factors, balanced against the long-term risk of treatment side effects. Identifying FH early and optimally lowering LDL-C
over the lifespan reduces cumulative LDL-C burden and offers health and socioeconomic benefits. To drive policy change for timely detection
and management, we call for further studies in the young. Increased awareness, early identification, and optimal treatment from childhood are
critical to adding decades of healthy life for children and adolescents with FH.
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Introduction
On his 10th birthday, a boy whose father died exactly 1 year ago aged
30 years, comes to consult you with his mother. The mother is worried
that her son will have the same fate, because he also has bad cholesterol.
What is your approach in this case?
Familial hypercholesterolaemia (FH) is a common genetic
cause of premature coronary heart disease (CHD). With one very
rare recessive exception, FH is an autosomal dominant disorder.
Both homozygous and heterozygous FH result in markedly
reduced hepatic capacity to clear atherogenic cholesterol-rich low-
density lipoproteins (LDLs) fromthe circulation, with consequent ac-
cumulation of LDL cholesterol (LDL-C).1 In severe cases, LDL-C
levels exceed 13 mmol/L (500 mg/dL).2 Beginning in the foetus, sus-
tained exposure of the arterial wall to elevated LDL-C levels acceler-
ates cholesterol deposition and vascular inflammation, developing
atherosclerosis, especially in the coronary arteries and aorta, and
premature CHD.3,4
Heterozygous FH(HeFH) is common(Figure 1A), present in1 per
200–250 of the general population, about two-fold higher than previ-
ously thought.2,5,6 Among a CHD-free control population, 1 in 217
carried a mutation in the gene encoding the LDL receptor (LDLR)
and had LDL-C .190 mg/dL.7 Consequently, there are potentially
as many as 4.5 million individuals in Europe with HeFH and probably
35 million worldwide (Figure 1B), of whom 20–25% are children and
adolescents. Given that there are 255 worldwide births per minute,8
one baby is born with FH every minute. Children with untreated
HeFH have a dramatic increase in risk of premature CHD after age
20 years.9,10 Familial hypercholesterolaemia in its homozygous form
(HoFH) is a rare disease with an estimated prevalence of 1 per 160
000–300 000 in European populations.2,11 Individuals with HoFH
areatextremelyhighriskand, if untreated,manywillmanifest coronary
or other cardiovascular disease in childhood or adolescence.
Familial hypercholesterolaemia is diagnosed either on phenotypic
criteria, involving an elevated LDL-C level plus a family history of ele-
vated LDL-C, premature CHD, and/or genetic diagnosis, or with
genetic testing. With fewexceptions, however, FH is underdiagnosed
and undertreated globally,5 and systematic screening strategies are
inconsistently implemented.12 Given the proven atherogenicity of
LDL-C in experimental models and in humans with FH, with evidence
that exposure to even moderate hypercholesterolaemia increases
the long-term risk of a new CHD event,13 and given the lifelong
benefit of genetically determined low LDL-C concentrations,14
there is an urgent need to identify and treat FH early to maximize
therapeutic benefit (Table 1). Importantly, statins are safe and effect-
ive in lowering LDL-C in children,15 restore endothelial function, and
regress thickening of the intima of the vessel wall at a young age.16 –18
The aim of this consensus paper is to encourage improvement in
early detection, diagnosis and treatment of FH by creating a para-
digm shift in its clinical perception in children and adolescents. We
discuss the current status of pathophysiology, diagnosis, genetic
testing, screening and management of FH. Figure 2 demonstrates
the potential of early recognition of FH, combined with treatment
from a young age, to substantially delay atherosclerosis progres-
sion. New findings support our recommendations to improve rec-
ognition and initiation of early treatment with lifestyle, diet, and
pharmacotherapy.19
Pathophysiology
Genetic causes
Familial hypercholesterolaemia is most often caused by mutations in
the LDLR gene, resulting in absent or dysfunctional receptors on the
surface of hepatocytes, identifying the liver as the principal site of LDL
catabolism. More than 1700 mutations in the LDLR gene on chromo-
some 19 have been identified, of which 79% are probably expressed
as a hypercholesterolaemic phenotype.20 Defects in the genes en-
coding apolipoprotein B (APOB) and proprotein convertase subtili-
sin/kexin type 9 (PCSK9) account for 5% and ,1% of FH cases,
respectively. The LDL receptor adaptor protein (LDLRAP1) gene is
a very rare recessive form of FH.5,21 However, 5–30% of cases of
phenotypic FH may arise from mutations in unidentified genes, or
have a polygenic cause as distinct from a dominantly inherited
disorder.22 –24 All of the monogenic defects result in reduced
efficiency of LDL uptake and clearance in hepatocytes and increased
circulating total cholesterol and LDL-C concentration. Inheritance of
a mutation in the gene from one parent causes HeFH; inheritance of a
mutation from each parent causes HoFH. Many individuals consid-
ered homozygous have two different genetic defects related to
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LDLR (i.e. compound HeFH), with mutations inAPOBor PCSK9 genes,
as well as an LDLR mutation.11
Early atherosclerotic disease
In FH, attenuated clearance of plasma LDL-C by the LDL receptor
leads to increased numbers of circulating LDL which penetrate and
then accumulate in the artery wall, become oxidatively modified,
and subsequently initiate an inflammatory response, which results
in vascular injury and formation of atherosclerotic plaque.25,26 Add-
itional alterations in the lipoproteinprofile in FHmay involveelevated
levels of lipoprotein(a) [Lp(a)] and triglyceride-rich lipoprotein rem-
nants, together with low levels of dysfunctional high-density lipopro-
teins (HDLs), which collectively may contribute to accelerated
atherosclerosis and CHD.27,28
Figure 1 Prevalence of familial hypercholesterolaemia. (A) Familial hypercholesterolaemia is more common than other genetic diseases.
1 Genetic Alliance UK. Incidence of genetic disorders. http://www.geneticalliance.org.uk/education3.htm (13 February 2015); 2 Streetly et al.140
FH, familial hypercholesterolaemia; PCKD, polycystic kidney disease. (B) The estimated prevalence of FH globally, based on estimated frequencies
of 1 : 500 and 1 : 200 (as suggested by recent research), reproduced with permission from Nordestgaard et al.5
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Both pre-mortem (the Bogalusa Heart Study) and post-mortem
studies (the Pathobiological Determinants of Atherosclerosis in
Youth [PDAY] study) have revealed a strong, continuous and
graded relationship between non-HDL cholesterol levels (i.e. total
cholesterol – HDL-C, comprising the atherogenic apoB-containing
lipoproteins) and atherosclerotic disease.29,30 Indeed, every
0.25 mmol/L (10 mg/dL) increment in non-HDL-C is associated
with an increase in atherosclerotic burden equivalent to 1 year of
aging. Although pathology studies have not been systematically per-
formed in children and adolescents with FH, observations in
non-FH individuals strongly suggest that very high LDL-C levels
sustained from childhood and adolescence in FH subjects would be
associated with future vascular disease. Collective evidence demon-
strates that elevated circulating markers of vascular inflammation and
endothelial dysfunction are present in children with FH, reflecting
early atherogenesis.31
Increased carotid intima-media thickness (cIMT) and detection of
coronary artery calcification by computed tomography (CT) scan-
ning are confirmed markers of early atherogenesis.31 A systematic
review of published data shows that cIMT is higher in phenotypic
FH patients (from age 10 years) than normolipidaemic controls,
and that this difference directly relates to LDL-C levels.32 The differ-
ence in mean cIMT between children with FH and unaffected siblings
may be significant as early as age 7 years (Figure 3A).33 Similar findings
were observed for mean femoral artery IMT.34 Coronary calcifica-
tion is present in 25% of 11–23 year olds with phenotypic HeFH,
Table 1 Key points about familial hypercholesterolaemia
† FH is one of the most common genetic disorders, affecting 1 : 200 to
1 : 250 people in the European population, inherited in an autosomal
dominant fashion.
† HeFH, and to an even greater degree HoFH, can be disabling at a
young age and shorten life expectancy.
† If LDL-C levels are .13 mmol/L (500 mg/dL) and paediatric
manifestations include premature CHD, aortic valve disease, and
tendon xanthomas in the hands and Achilles tendons, homozygosity
is assumed. However, HoFH may be considered at lower LDL-C
levels following recent recognition of the clinical and genetic
heterogeneity of FH.
† The presence of FH presents a psychological challenge for families
because of the inherited nature of the condition, the lack of early
symptoms in HeFH, and the need for long-term lifestyle changes and
pharmacotherapy.
† Early detection of FH and early initiation of lifestyle and
pharmacological treatment is imperative to reduce the lifelong
burden of elevated LDL-C levels.
Figure 2 Development of early atherosclerotic vascular disease in familial hypercholesterolaemia showing the potential impact of early recog-
nition and treatment on evolution of the condition. CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol.
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and especially in the aorta in most adolescents with HoFH, although
coronary and aortic calcium score is rarely, if ever, positive in pre-
adolescent HoFH children.11,35 –37 In contrast, coronary calcium is
barely detectable in atherosclerotic lesions in adolescents in
the general population.38 When compared with children with LDLR-
defective alleles, those with LDLR-null (complete loss of function)
alleles have higher LDL-C levels, more advanced atherosclerosis
and, correspondingly, increased cIMT.34,39
Diagnosis
Paediatric FH is diagnosed phenotypically by the presence of an
LDL-C level consistent with FH plus a family history of premature
CHD and/or baseline high cholesterol in one parent and/or an
FH-causing mutation (Table 2).11,21 Childhood is the optimal period
to discriminate between FH and non-FH on the basis of LDL-C con-
centration, due tominimal dietary/hormonal influences.After dietary
intervention, any child with an LDL-C level ≥5 mmol/L (190 mg/dL)
has ahighprobabilityof genetically basedFH. If there is a family history
of premature CHD in close relatives and/or a baseline high choles-
terol in one parent, an LDL-C ≥4 mmol/L (160 mg/dL) is indicative
of a high probability of genetically based FH.
Detection of a pathogenic mutation, usually in the LDLR gene, is
the gold standard for diagnosis of FH.6,21,40 –43 A child of a parent
with FH has a 50% probability of inheriting FH, thereby emphasizing
the importance of a family pedigree to identify relatives for screening.
Typically, there will be a marked difference in LDL-C levels between
children with and without genetically defined FH. In one study, a
functional mutation was identified in 95% of children meeting pheno-
typic criteria for FH and with an autosomal dominant pattern of in-
heritance of hypercholesterolaemia.24 If the parent has a genetic
diagnosis and the child has an LDL-C ≥3.5 mmol/L (130 mg/dL), an
LDLR mutation is to be anticipated.40
The applicability of current diagnostic tools varies. While the
Dutch Lipid Clinic Network criteria are not valid in children,41 the
Simon Broome criteria have specific cut-offs for LDL-C in this
group. The LDL-C threshold is 4 mmol/L (160 mg/dL) in children
with FH aged ,10 years.24,44 A lower LDL-C threshold (3.5 mmol/L
or 130 mg/dL) may be used when children are tested as part of
Figure 3 Carotid intima-media thickness is a marker of early
atherogenesis in children with familial hypercholesterolaemia.
(A) Increased carotid intima-media thickness is already evident at
age 7 years in familial hypercholesterolaemia children. Data from
Kusters et al.33 After 10 years treatment with a statin, while mean
carotid intima-media thickness is higher in familial hypercholester-
olaemia children than their unaffected siblings (B), there is no signifi-
cant difference between the two groups in carotid intima-media
thickness progression over this period (C). Data from Kusters
et al.98 Data in (B) and (C) are given as mean+ SEM and are adjusted
for age, gender, blood pressure, body mass index, smoking, and
family relations. cIMT, carotid intima-media thickness; FH, familial
hypercholesterolaemia; NS, not significant.
Table 2 Diagnosis of familial hypercholesterolaemia in
children and adolescents
† Family historyof premature CHD plus high LDL-C) levels are the two
key selective screening criteria: (F + H ¼ FH).a
† Cholesterol testing should be used to make a phenotypic diagnosis.
† An LDL-C level ≥5 mmol/L (190 mg/dL) on two successive
occasions after 3 months diet indicates a high probability of FH. A
family history of premature CHD in close relative(s) and/or baseline
high cholesterol in one parent, together with an LDL-C ≥4 mmol/L
(160 mg/dL) indicates a high probability of FH. If the parent has a
genetic diagnosis, an LDL-C ≥3.5 mmol/L (130 mg/dL) suggests FH
in the child.
† Secondary causes of hypercholesterolaemia should be ruled out.
† DNA testing establishes the diagnosis. If a pathogenic LDLR mutation
is identified in a first-degree relative, children may also be genetically
tested.
† If a parent died from CHD, a child even with moderate
hypercholesterolaemia should be tested genetically for FH and
inherited elevation in Lp(a).
aAcknowledgement to the FH Foundation (http://thefhfoundation.org/).
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cascade screening.40,45 LDL-C levels should be measured at least
twice over 3 months to confirm the diagnosis of FH.5,6 An LDL-C
level .13 mmol/L (500 mg/dL) is consistent with phenotypic
HoFH, but may be lower given recent recognition of the clinical
and genetic heterogeneity of FH.2,11
Factors that complicate diagnostic accuracy include the presence
of multiple genes that have a small positive effect on LDL-C concen-
tration, raising levels to those consistent with FH, or the presence of
‘compensatory’ genes that lower LDL-C below thresholds defined
above.46– 48 There is also overlap between those with HeFH and
HoFH at LDL-C levels of 8–13 mmol/L (300–500 mg/dL).2,11
Secondary causes of elevated LDL-C, including hypothyroidism,
nephrotic syndrome, obstructive liver disease, obesity, anorexia
nervosa, and drug treatment (e.g. isoretinoids) should be considered
in patient evaluation.42– 44,49 Sitosterolaemia, particularly if xan-
thoma are present, or cholesteryl ester storage disease when liver
transaminases are elevated, although extremely rare, should also
be considered.41 Recent evidence suggests that the marked hyper-
cholesterolaemia in sitosterolaemia may be transient and also diet
dependent.50
Genetic testing of families
It is best practice to first genetically test a phenotypically
affected parent or a second-degree relative in the absence of a
parent.39,42,51,52 If a mutation is identified, genetic testing and coun-
selling should be offered to all family members, ideally co-ordinated
centrally in association with a clinical genetics service.39,53 To in-
crease acceptability, genetic testing for FH in children should be avail-
able using DNA extracted from buccal samples.39 The psychological
sequelae of genetic tests must be considered, with pre-test counsel-
ling essential to the consent/assent procedure, taking account of the
child’s level of comprehension and parental literacy.51,52 In circum-
stances in which FH is suspected but no parents or second-degree
relatives are available or the parents refuse testing, afterobtaining ap-
propriate assent/consent genetic testing and measurement of Lp(a)
should be carried out in minors, especially if a parent died from
CHD and the child has only moderate hypercholesterolaemia.
Laboratory aspects
Laboratories for genetic analyses should be fully accredited by local,
national, or international authorities. Established procedures should
be followed for classifying variants as clearly pathogenic (a mutation),
clearly non-pathogenic (a benign variant) or of uncertain significance
(5–8% of molecular diagnostic reports), based mainly on in silico as-
sessment coupled with a search of the literature and established data-
bases.6,39 Failure to detect a mutation does not exclude a diagnosis of
FH. One reason may be insufficient sensitivity or specificity of the
technology; additionally, some paediatric phenotypic index cases
do not have known FH-causing mutations.
Most laboratories involved in FH genetic testing will utilise a
number of mutation detection methods, including Sanger-based
exon-by-exon sequence analysis and Multiplex Ligation Probe Amp-
lification for large deletions and duplications; whole- and targeted
exome sequencing are newer options.21,22 All results from commer-
cial chip or kit technology that identify a gene variant as being present
should be confirmed using a second validated testing method. ‘Next
Generation’ exome sequencing is a newer option, which also identi-
fies insertions and deletions.21,22,48
Screening
Screening for FH meets World Health Organization guidelines:54
childhood represents a latent stage of the disease, a simple test to
diagnose FH acceptable to the general population exists, there is
effective treatment, and case-finding can be made part of routine
medical practice. Table 3 summarizes key features of potential
screening strategies. Research is needed to ascertain the exact age
to begin treatment and the long-term safety of cholesterol-lowering
treatment.55
In families with a known LDLR mutation, molecular testing is the
most reliable and effective method to identify affected family
members including children and adolescents. Theoretically, genetic
testing of first-degree relatives has a sensitivity and specificity of
100%, whereas for clinical diagnosis, sensitivity and specificity is in
the range of 70–85%.44 In the Netherlands, .28 000 individuals
with FH have been identified, almost 23 000 via cascade screening,
carrying .500 different mutations.56,57 But even with this strategy,
30% of the 33 300 estimated cases are not identified,5 due to lack
of an index case. In the Norwegian genetic screening programme,
.5600 individuals of the estimated 15 000–20 000 FH patients
have been identified, carrying .140 different mutations. Legal
restrictions require relatives to contact family members directly,
which restricts the efficiency of detecting new FH cases. Clinical diag-
nosis of FH in general practice has a sensitivity of 46% and a specificity
of 88%.58 In the UK, a family cascade testing approach for FH is
recommended, starting with adults and proceeding to testing chil-
dren from the age of 10 years in families known to have a clear diag-
nosis of FH. The programme has been fully implemented in Wales,
Scotland, and Northern Ireland.59
Universal screening of children for hypercholesterolaemia in
Europe has only been implemented in Slovenia from the age of
5 years.60 In the USA, universal screening at age 9–11 years has
been recommended, in part because selective screening based on
family history is not efficient in identifying children with LDL-C in
the FH range.61,62 Screening can be performed in conjunction with
routine health visits such as at the time of immunization,44 and
cascade screening of first-degree family members can follow
Table 3 Screening for familial hypercholesterolaemia
in children and adolescents
† If DNA testing is available, cascade screening of families is
recommended using both a phenotypic and genotypic strategy. If
DNA testing is not available, a phenotypic strategy based on country,
age- and gender-specific LDL-C levels should be used.
† Children with suspected HeFH should be screened from the age of
5 years; screening for HoFH should be undertaken when clinically
suspected (both parents affected or xanthoma present) and as early
as possible.
† Age at screening should be similar for boys and girls.
† Universal screening in childhood may also be considered.
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identification of a child with severely elevated LDL-C. However, the
acceptability, practicability, specificity, and cost-effectiveness of this
approach have yet to be evaluated.63
Other risk factors
Given independent associations of type 2 diabetes, hypertension,
tobacco use (including passive smoking), and obesity with athero-
sclerosis development,38 a patient with FH and an additional
risk factor is at even greater risk than a patient with FH alone, as
supported by natural history data in FH cohorts.64,65 There is also
prognostic value in screening for plasma lipoprotein(a) [Lp(a)] con-
centration given that high Lp(a) (.50 mg/dL or 80th percentile)
increases risk for premature CHD (by 1.5-fold).6,40,66 In childhood,
FH may co-exist with other diseases known to accelerate athero-
sclerosis, including type 1 diabetes mellitus, chronic kidney disease,
connective tissue disorders, and HIV infection.67
Management
Early treatment of FH can reduce LDL-C burden (Figure 4), improve
endothelial function, substantially attenuate the progression of
atherosclerosis (Figure 3B and C ), and improve coronary outcomes
(Figure 5),17,18,68–71 all of which emphasizes the rationale for
greater long-term benefit with initiation of treatment earlier rather
than later in life.70,71 Furthermore, long-term follow-up from
statin trials, albeit not specifically in FH patients, suggests a legacy
effect, i.e. better CHD outcomes in those initially randomized to
statin treatment.72,73 Table 4 summarizes key points related to FH
management.
Diet and risk factor control
Diet and lifestyle underpin the management of FH in children. In
considering dietary fat content, the major dietary drivers of serum
Figure 4 Impact of statin treatment on cholesterol burden in familial hypercholesterolaemia. Early initiation of statin treatment reduces the low-
density lipoprotein cholesterol burden* in subjects with familial hypercholesterolaemia. Reproduced with permission from Vuorio et al.70 (A): Cu-
mulative low-density lipoprotein cholesterol burden byage of 18 years is 15% lower in familial hypercholesterolaemia subjects treated with low dose
statin from age 10 years (70 mmol) than in untreated familial hypercholesterolaemia subjects (80 mmol). (B) Cumulative low-density lipoprotein
cholesterol burden of a 55-year-old non-familial hypercholesterolaemia subject is 160 mmol. In an untreated familial hypercholesterolaemia
subject, this is attained by age 35 years, but is delayed in familial hypercholesterolaemia patients treated from age 18 years (48 years), and further
delayed in those treated from age 10 years (53 years). *For calculation of the low-density lipoprotein cholesterol burden, the following assumed
mean low-density lipoprotein cholesterol values were used. Non-familial hypercholesterolaemia subjects: 2.0 mmol/L for the age range of 0–15
years; 2.5 mmol/L for 15–24 years; 3.0 mmol/L for 25–34 years; 3.5 mmol/L for 35–44 years; and 3.5 mmol/L for 45–54 years. Familial hyperchol-
esterolaemia subjects: 4.5 mmol/L in untreated familial hypercholesterolaemia patients; 3 mmol/L in familial hypercholesterolaemia patients treated
during the age range of 10–18 years, and 2.5 mmol/L in familial hypercholesterolaemia patients with treatment started at the age of 18 years. FH,
familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol.
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cholesterol levels are saturated fats and trans fats with a small
contribution from dietary cholesterol.74,75 Limitation of foods high
in saturated fat will secondarily limit dietary cholesterol intake;
cholesterol-containing foods without saturated or trans fats may
be allowed.76 Reduction of saturated fat intake has not been
associated with altered physical growth during long follow-up.77
Consequently, the Panel recommends a heart-healthy, fat-modified
diet (,30% of calories from total fat,,7% of calories from saturated
fat, and ,200 mg of cholesterol/day),68,78 ideally incorporating
nutrient-dense foods with appropriate energy to maintain optimal
body weight. Intake of fruit and vegetables, whole grains, low-fat
dairy products, beans, fish, and lean meats should be encouraged.
Diet choices are by nature diverse; emphasis should be on a culturally
acceptable heart-healthy diet, such as Mediterranean-style diets.
There should be annual or bi-annual monitoring of weight, growth
and developmental milestones. Physical activity should be promoted
and smoking strongly discouraged. Identifying children with FH early
ensures that adherence with lifestyle interventions is established
before puberty. Other cardiovascular risk factors should be moni-
tored and treated if indicated.
Pharmacotherapy for heterozygous
familial hypercholesterolaemia
Statins are the cornerstone of FH management. Simvastatin,
lovastatin, atorvastatin, pravastatin, fluvastatin and rosuvastatin are
approved in the USA and Europe for use in children with FH. In the
USA, these are approved from age 10 years, except for pravastatin
which is approved from age 8 years.6 Prescribing information is
broadly similar in Europe, although rosuvastatin is approved from
the age of 6 years. Atorvastatin is approved from age 6 years in
Australia. Treatment may be started earlier in severe cases.79 The
short-term efficacy and safety of these statins, including during
puberty, have been confirmed.15,68,80
Treatment should be initiated at the lowest recommended dose
and up-titrated according to the LDL-C lowering response and
tolerability. Evidence for an absolute target for LDL-C in children
with FH does not exist. Expert consensus recommends a target
LDL-C level ,3.5 mmol/L (130 mg/dL) from age 10 years, or
ideally 50% reduction from pre-treatment levels for children 8–10
years, particularly in those with high-risk conditions or other major
risk factors.6,11,42,43,67 In patients with chronic kidney disease, a
statin that is not excreted by the kidney, such as atorvastatin or sim-
vastatin, should be used. Clinicians should be aware of the potential
fordrug-drug interactionswith statins, notably, fordrugsmetabolised
by cytochrome P450 (CYP) 3A4 with simvastatin and atorvastatin,
and for drugs metabolised by CYP 2C9 with rosuvastatin and
fluvastatin. Pravastatin, although a weak statin, does not interfere
with CYP enzymes and is therefore a safe drug for initiating treatment
in children.
Additionof ezetimibe orabile-acid sequestrantmay be required to
attain LDL-C goal in some patients.42,43,81,82 Ezetimibe is approved
for use from age 10 years in the USA and Europe, and is very well tol-
erated with minimal side effects. The bile-acid sequestrants cause
gastrointestinal side effects; colesevelam is the best tolerated of
these agents and is approved in the USA from age 10 years although
not in Europe.83 As these agents can affect the absorption of folate
and fat-soluble vitamins, appropriate supplementation and monitor-
ing will be required with longer-term use. Niacin should rarely be
used to treat paediatric FH due to poor tolerability and concerns
regarding the risk of glucose intolerance, myopathy, hyperuricaemia
and hepatitis. For all treatments, drug dosing regimens should follow
those evaluated in clinical trials and approved by local regulatory
agencies, except in severe FH or when FH is complicated by addition-
al cardiovascular risk factors, in which expert clinical judgment is
Table 4 Clinical management of FH in children and
adolescents
† Early identification of children with FH ensures that adherence with
lifestyle intervention is already established before puberty.
† Children with HeFH should be treated with a fat-modified,
heart-healthy diet at diagnosis, and begin statins at age 8–10 years.
† In HoFH, pharmacologic treatment should start at diagnosis.
† Early initiation of lifestyle is essential for ensuring long-term
adherence.
† Children diagnosed with FH should have lipoprotein(a) [Lp(a)]
measured for risk stratification.
† Boys and girls should start treatment at similar ages.
† For children aged 8–10 years, the Panel recommends that LDL-C is
ideally reduced by 50% from pre-treatment levels.
† For children aged ≥10 years, especially if there are additional
cardiovascular risk factors, including elevated Lp(a), the target LDL-C
should be ,3.5 mmol/L (130 mg/dL).
† The benefits of LDL-C reduction should be balanced against the
long-term risk of treatment side effects.
† Adherence should be checked if HeFH children fail to achieve LDL-C
targets with combination lipid-lowering treatment. If patients are
non-adherent, consider referral to a dedicated, multidisciplinary
clinic.
† Children with HoFH should be referred to and cared for at a
specialised centre.
Figure 5 Reduction in low-density lipoprotein cholesterol
burden associated with early initiation of statin treatment in chil-
dren with familial hypercholesterolaemia translates to improve-
ment in coronary outcomes. Kaplan–Meier curves of event-free
survival in a cohort of 214 familial hypercholesterolaemia subjects
treated from childhood (n ¼ 214) compared with their parents
with familial hypercholesterolaemia, treated from adulthood
(n ¼ 156). Data from Braamskamp et al.99 FH, familial hypercholes-
terolaemia.
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needed to weigh the risks vs. benefits of more aggressive treatment
(Table 4).
Dietary supplementation with functional
foods
Several controlled clinical trials have shown that foods containing
added plant sterols/stanols (1.5–3 g/day) reduce LDL-C levels by
9–19% in children and adolescents with FH (aged 4–15 years).84,85
There was, however, no improvement in endothelial function
despite significant LDL-C lowering.86,87 Reduction in levels of some
fat-soluble vitamins andcarotenoids can be compensated byensuring
adequate intake of fruit and vegetables.84 Currently, the use of foods
enriched with plant sterols/stanols is not recommended for children
under 6 years.84
A wide range of other nutrients and supplements, including
psyllium-enrichedcereal, garlic extract,omega-3 fattyacids, rapeseed
oil and soy protein, have been assessed in small studies in FH patients
and in children with hypercholesterolaemia.88–96 No firm recom-
mendation regarding the use of any of these agents in children and
adolescents can be made at this time.
Monitoring therapy and adherence
Life-long treatment critically involves collaboration between families
and physicians. Recommendations for monitoring the safety and tol-
erability of lipid-modulating agents in paediatric FH are similar to
those in adults (Table 5).5,6,61 Particular vigilance is required in
patients receiving higher statin doses, or in those predisposed to
statin side effects due to participation in vigorous contact sports or
the use of other medication, such as fibrates (notably gemfibrozil).
Adolescent girls should be counselled to suspend statin therapy
when contemplating pregnancy (see below).
At recommended statin doses, the dose–response curve is not
linear. Most of the reduction in LDL-C occurs at lower doses, with
each subsequent doubling in dose yielding incremental reductions
of 6–7% in LDL-C.97 Therefore, the need to intensify treatment
with higher doses should be balanced against any long-term side
effects due to greater exposure to medication. While more data con-
cerning myopathy and the risk of diabetes in children treated with
statins over many years is needed, recent long-term follow-up
showed an excellent safety profile (Table 6).98 Even more important-
ly, at the age of 30 years, CHD-free survival was 100% in FH children
initiated early on statin vs.. 93% in their affected parents (P ¼ 0.02)
(Figure 5).99
Adherence and response to statin therapy shouldbechecked inFH
patients who fail to achieve target LDL-C levels despite polypharma-
cotherapy. Non-adherent patients can be optimally managed in a
Table 5 Monitoring treatment in FH children and
adolescents
† Hepatic aminotransferases, creatine kinase (CK) and creatinine levels
should be measured before starting treatment.
† After starting treatment, lipid levels, weight, growth, physical and
sexual development, and hepatic aminotransferases should be
monitored.
† Hepatic aminotransferases should be monitored at least every 3
months if there is a history of liver disease, or more frequently if levels
rise to 3-fold greater than the upper limit of normal; bilirubin may be
used to gauge liver toxicity.
† Plasma CK levels should be measured if musculoskeletal symptoms
are reported.
† Fasting plasma glucose and/or random glycated haemoglobin should
be measured every 6 months in children on higher doses of statins
who are obese or have impaired glucose tolerance.
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Table 6 Safety indices of familial hypercholesterolaemia subjects, initiated on pravastatin in childhood (aged 8–18 years)
and treated for 10 years, compared with their unaffected siblings
FH (n5 194) Siblings (n5 83) P-value
Effect on liver function; no. (%) of patients
 in AST .3 × ULN 1 (0.5) 1 (1.1) 0.26
 in ALT .3 × ULN 1 (0.5) 0 0.51
 in CK .10 × ULN 0 2 (2.1) 0.03
Effect on renal function
eGFR (mL/min/1.73 m2), median (IQR) 127 (121–131) 125 (119–130) 0.05
Diabetes, n (%) 1 (0.5) 1 (1.2) 0.55
C-reactive protein (mg/dL), median (IQR) 0.9 (0.3–2.3) 1.2 (0.3–3.0) 0.27
Age at menarche (year), mean (95% CI) 13.1 (12.2–13.4) 13.4 (12.8–14.1) 0.27
Level of education, n (%)
Lower 31 (17.1) 13 (16.0) 0.96
Middle 71 (39.2) 33 (40.7)
Higher 79 (43.6) 35 (43.2)
Adapted from Kusters et al.98
ALT, alanineaminotransferase;AST, aspartateaminotransferase;CI, confidence interval; CK, creatine kinase; eGFR, estimatedglomerular filtrationrate; IQR, interquartile range;ULN,
upper limit of normal range.
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dedicated, multidisciplinary clinic with possible support from psy-
chologists.100 Action plan interventions may be more effective in
FH than interventions aimed at altering perceptions about statin
therapy. Health literacy must be also considered. Although rare in
childhood, patients who are intolerant of pharmacotherapy,
notably statins, require special support and follow-up.41,100
Carotid IMT imaging and coronary artery calcium assessment have
been used in research settings to evaluate early subclinical athero-
sclerosis and response to statins in FH.33,34,98,101,102 Long-term
statin treatment initiated during childhood in patients with FH was
associated with normalization of cIMT progression during aging
(Figure 3B and C ).98 In a recent trial, children with HeFH aged from
6 years treated with rosuvastatin showed slowing of cIMT progres-
sion after 2 years, whereas in previous reports, untreated FH children
had shown marked progression over this time.18,103 There are,
however, limitations to the use of these surrogate markers in risk
stratification of FH patients,5,40 and in monitoring treatment in an in-
dividual,104 as well as uncertainties relating to the potential benefit of
repeat measurement, independent of LDL-C lowering, on clinical
outcomes. Consequently, the use of IMT for monitoring patients is
not recommended until evidence of its clinical utility is established.
Nonetheless, the use of vascular imaging, including IMT, can be
highly informative for research purposes. Coronary artery calcium
measurement is not recommended because it may be absent when
significant atherosclerosis is present, does not usually develop until
adulthood, and importantly, repeated CT scans carry an increased
lifetime risk of exposure to radiation.
Paediatric patients with uncomplicated and well-controlled
phenotypic FH may be managed by experienced primary care practi-
tioners.5,6,105 However, patientswith severelyelevatedLDL-C levels,
multiple cardiovascular risk factors or complications of pharmaco-
logic therapy, or those with HoFH, should be managed with specialist
care involving both a (paediatric) cardiologist and lipidologist.6 Family
and transitional care clinics are recommended.41 All patients should
be offered an annual structured clinical review.6,53
Contraception and pregnancy-related
issues
The risks for the patient and foetus should be discussed at least annu-
ally with all women and girls of childbearing age. Low oestrogen oral
agents, intra-uterine devices and barrier methods are the preferred
contraceptive measures in adult women with FH.106 Oral contracep-
tives, especially those with high oestrogen content, may increase tri-
glyceride and LDL-C concentrations in FH, so monitoring of the lipid
profile after initiation of these agents is required. More research is
needed on the long-term implications of oral contraceptive use in FH.
Counselling is recommended for all women considering preg-
nancy,6,106– 108 especially when both prospective parents have FH,
because of the 25% risk of having a child with HoFH. Statins should
be discontinued 3 months before planned conception and during
pregnancy and lactation;106 however, women who become pregnant
accidentally while taking a statin should be reassured that the likeli-
hood of foetal complications is small.109,110 In most patients, statin
therapy can be interrupted safely during pregnancy and lactation, es-
pecially when treatment is started early in life. Bile-acid resins are the
only safe agents for management of hypercholesterolaemia during
pregnancy and breast-feeding, although efficacy is modest and poor
gastrointestinal tolerability is a major problem;107 colesevelam is
the most tolerable. In women with HoFH, LDL apheresis can be
safely and successfully continued during pregnancy.106,107
Given increases in maternal cholesterol levels during preg-
nancy,111 maternal FH has been associated with atherosclerosis in
the uteroplacental spiral arteries, as well as hypercoagulation, local
thrombosis, placental infarctions, and placental insufficiency. Avail-
able evidence, however, indicates that women with FH are not at
increased risk for pre-term delivery, and infants are not at increased
risk of congenital malformations or intra-uterine growth retard-
ation.112 While neonates born to mothers with FH have altered
haemostatic profiles regardless of FH status,113 and infants born to
hypercholesterolaemic mothers have increased numbers of fatty
streaks in their aortas,114 the long-term consequences of these man-
ifestations are uncertain. More data on the outcomes of pregnancy in
women with FH and the effect of statins on fertility and the foetus in
the first trimester are required.115,116
Homozygous familial
hypercholesterolaemia
Homozygous familial hypercholesterolaemia has been the subject of
a recent European Atherosclerosis Society Consensus Paper.11 Low-
density lipoprotein cholesterol levels in children with HoFH are typ-
ically .13 mmol/L (500 mg/dL), although affected individuals with
lower levels have been identified with wider and increased use of
genetic testing.2 Homozygous familial hypercholesterolaemia
should be strongly suspected if the parents have cholesterol levels
compatible with heterozygous status; if parental cholesterol levels
are normal, a recessive form of FH due to mutations affecting the
LDLRAP1 should be considered and sitosterolaemia excluded.117
Xanthomas can appear within the first few months of life and
usually before 10 years of age, and are often the reason why these
children come to medical attention; however, their absence or late
appearance does not exclude the diagnosis of HoFH.118
Children with suspected HoFH should be referred promptly to
specialized centres due to the aggressive nature of this condition.
Earlier cardiovascular symptoms and signs are typically related to
aortic stenosis and regurgitation due to massive accumulation of
cholesterol in the valvular and supravalvular regions of the aortic
valve,118 as well as to coronary ostial stenosis, which contrasts with
the distal coronary artery involvement seen in HeFH.11 Angina pec-
toris, myocardial infarction and death in early childhood have been
reported,49,119 – 121 although the first major cardiovascular events
usually occur during adolescence, depending on the severity of the
mutation(s).118 If HoFH is suspected, an extensive cardiovascular
evaluation is imperative, with coronary CT angiography recom-
mended toevaluate the aorta and coronary arteries and magnetic res-
onance imaging toevaluate theaorta. Invasive coronaryangiography is
indicated on a patient-by-patient basis depending on clinical status and
outcome of non-invasive cardiac investigations. Follow-up investiga-
tions should be conducted regularly to monitor aortic and coronary
artery disease based on the age of the child and disease severity.
A very aggressive cholesterol-lowering approach should be
initiated as soon as possible to prevent or delay the development
A. Wiegman et al.2434
of CHD.11 Treatment with a statin and ezetimibe must be started at
diagnosis. If available, lipoprotein apheresis should be started as soon
as technically possible; this may be as early as age 2 years in specialized
centres.11 In retrospective studies, both approaches have delayed
cardiovascular events and increased survival.122,123 Despite the
known risks, liver transplantation is increasingly considered as a
therapeutic approach in difficult cases.11 Two new agents, oral lomi-
tapide, a microsomal triglyceride transfer protein inhibitor, and in-
jectable mipomersen, an antisense RNA therapy, both of which
target hepatic production of atherogenic apoB-containing lipopro-
teins, were recently approved in the USA as adjunct therapy for
HoFH in patients aged ≥18 and ≥12 years, respectively; lomitapide
is also approved in Europe and Canada. Although there are no data in
children, it is pertinent that lomitapide has been shown to be effective
in HoFH patients on apheresis.11,124 With both agents, fat accumula-
tion in the liver has been observed; other adverse effects include
gastrointestinal intolerability with lomitapide and injection site
reactions with mipomersen. Given these concerns, the long-term
use of these new agents may be limited. Of novel therapies in devel-
opment, monoclonal antibody therapies to PCSK9 (alirocumab,
evolocumab and most recently, bococizumab) show the most
promise, lowering both LDL-C and Lp(a),125 although patients
homozygous for LDLR-null mutations showed a poor therapeutic re-
sponse, as expected from the mechanism of action.126 Paediatric
trials of these agents are underway or planned.
Health economics of detection
and treatment of familial
hypercholesterolaemia
In adults, health economic modelling shows that FH treatment leads
to considerable savings on healthcare. Compared with universal
screening, cholesterol testing in patients in whom the causative mu-
tation is known, together with cascade testing of immediate family
and relatives using DNA information is very cost-effective, because
50% of them inherit the mutation.127 Furthermore, intensive
lipid-lowering therapy to reduce the LDL-C burden in FH patients
is cost-effective.128,129
Studies from the Netherlands,130 Spain,131 and the UK132 suggest
that thecostperLife Year Gained forDNA-based cascade testing and
intensive statin therapy in FH is in the region of E3000–E4000,
which compares favourably with other screening strategies, e.g.
mammography for breast cancer. Existing cost-effectiveness analyses
of cascade screening are limited by different methodologies and
assumptions,withmost studies fromEuropeancommunities andeva-
luations restricted to adults.133 Some experts recommend universal
screening,61,134 particularly in the young, although cost-effectiveness
has not been analysed.127 Where DNA testing is not feasible, it
remains to be seen whether screening with a lipid profile alone is
cost-effective, although preliminary data from the UK and USA
suggest this to be true.135,136
A recent report on the health, social, and economic benefits of
treating FH estimated that high-intensity statin therapy would lead
to 101 fewer cardiovascular deaths per 1000 FH patients treated
(between the ages of 30 and 85 years), compared with no treat-
ment.137 Extrapolating to the 500 million population of the EU
(with an estimated 1 000 000 [to 2 000 000] FH patients), roughly
E4700 million could be saved from cardiovascular events avoided if
all relatives of index cases were identified and treated optimally
over a 55-year period, equating to E86 million per year. Clearly,
more country-specific health economic evaluations, including esti-
mates of societal benefits that focus on the young, are critical to
drive policy change and government funding for early detection
and management programs for FH.
Gaps in evidence
This document is entirely consistent with current international guide-
lines for the care of patients with FH.6,134,138,139 However, all of these
documents recognize that gaps in evidence remain, which require
further study (Table 7). Recognition of the value of Mendelian ran-
domization studies as evidence for the benefit of lifelong low LDL-C
(e.g. due to loss-of-function genetic variants in PCSK9) in the context
of FH,14 together with observational studies comparing outcomes
of FH children with FH adult relatives, and equally long-term studies
of lipid lowering in FH cohorts, would address these gaps.
Conclusions
Returning to our case. . .
When the boy was 11, he was referred for genetic testing. A pathogenic
LDLR mutation within the promoter region was discovered, and he
started on lifestyle management. Statin treatment was initiated around
his 12th birthday. After nearly 20 years, he is achieving all treatment
goals. He is now older than his father was at time of death, and there is
no evidence of the chest pain his father first reported when he was 27
(3 years before his death), which was not thought to be angina pectoris.
Because of the young age. Recently, his youngest daughter of 5 was
found to carry the same gene promoter mutation, and is currently
managed with a heart-healthy diet. Within 3 years, she will start statin
therapy. Early identification and optimal treatment from childhood
should provide decades of healthy life for the man and his daughter.
Finally, 33 of the man’s relatives took advantage of cascade screening.
Fourteen had high LDL-C levels and were positive for the mutation; they
are now appropriately treated, with two cousins receiving stents. This
family scenario highlights the value of cascade screening for FH.
It is clear that for FH patients to gain maximum benefit from exist-
ing treatments, identification in early childhood is imperative to
Table 7 Gaps in evidence
† Evaluation of the potential contributions of invasive and non-invasive
cardiac imaging for assessment of clinical and incident atherosclerotic
vascular disease.
† Clinical trials showing reduction in coronary events as a consequence
of lowering of LDL-C, although such studies are not ethically
acceptable.
† Efficacy and acceptability of new biologics in refractory FH.
† Long-term safety of current and future cholesterol-lowering
treatments, including effects on future fertility.
† Cost–benefit analyses of FH identification in childhood.
† Value, cost-effectiveness, and acceptability of universal screening and
reverse cascade screening strategies.
† Organization of care between community and specialist settings.
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prevent atherosclerosis at the earliest stage of development.
Screening for FH in children should be country specific, utilizing
all existing screening strategies, including opportunistic screening
in the setting of a positive family history, and cascade screening
based on genetic testing where available (Algorithm, Figure 6). Uni-
versal screening might be considered by age 10 years in countries
where this is feasible, especially where founder effects with marked-
ly increased frequency of FH are prevalent, such as Quebec in
Canada, South Africa and Lebanon. Initiation of statin treatment
at a young age is safe in both the short and mid-term, and significantly
improves cardiovascular outcomes. Better education of young FH
patients, together with frequent follow-up, are critical for ensuring
long-term adherence.
Despite evidence gaps regarding the long-term safety and
cost-effectiveness of drug treatment from childhood, genetic
natural history studies confirm the benefit of lifelong low LDL-C
levels.14 Indeed, recent evidence highlighting the timeliness
of statin initiation in FH children on progression of surrogate
cardiovascular endpoints implies that statin-mediated LDL-C re-
duction prevents early cardiovascular events.18,32,33,70,97,98 Increas-
ing awareness of FH at both clinical and community levels, and
recognition and care of FH from childhood, are key to gaining
decades of healthy life in children and adolescents with this
common inherited disorder.
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Figure 6 Potential strategy for diagnosis of familial hypercholesterolaemia in children and adolescents.CHD, coronary heart disease; FH, familial
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≥5 mmol/L in achild afterdietary interventionoran low-density lipoprotein cholesterol level≥4 mmol/L in achildwith a family historyofpremature
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Appendix
European Atherosclerosis Society
Consensus Panel
This Consensus Panel was comprised of international experts recog-
nized forcontributions throughbasicorclinical research toFH inchil-
dren, as identified by literature searches. All experts possess
expertize in the areas of diagnosis and management of FH, genetic
testing and screening for FH, and/or the basic science of the
pathophysiology of premature atherosclerosis in FH. The Panel
includes a geographic distribution of experts representative of
the membership of the European Atherosclerosis Society. Officers
and members of the Executive Committee of the Society also
participated.
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Petri T. Kovanen, Jan Albert Kuivenhoven, Luis Masana, Børge
G. Nordestgaard, Leiv Ose, Pa¨ivi Pajukanta, Klaus G. Parhofer, Fred-
erick J. Raal, Kausik K Ray, Raul D. Santos, Anton F. H. Stalenhoef,
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Search strategy and consensus
process
In line with Consensus Panel policy for other papers published by
European Atherosclerosis Society Consensus Panels, this manu-
script used existing evidence evaluations to make recommenda-
tions supported by observational data. We searched Medline,
Current Contents, PubMed, the Cochrane Database, and relevant
references with the terms FH, inherited hypercholesterolaemia,
LDL-C, LDL receptor, apolipoprotein B, children, premature
atherosclerosis, event-free survival, diagnosis, treatment, statin,
ezetimibe, and PCSK9 inhibitor. Articles published in English
between 2000 and 2015 were included.
This review was based on discussions at two meetings of the Euro-
pean Atherosclerosis Society Consensus Panel in London and Lyon
organized and chaired by AW, MJC, and HNG, where the search
results and drafts of this review were critically appraised; the
review results primarily from a consensus of expert opinions.
AW, SSG, GFW, MJC, HNG, MC, and LO each drafted sections
and/or outline for the first version, and AW, SSG, and GFW were re-
sponsible for revision of the draft. As per the agreed policy,
recommendations were not codified for level of evidence nor
strength of recommendation, as this Consensus paper was intended
principally to raise awareness of FH among clinicians and to provide
clinical guidance in diagnosis and management, rather than as a spe-
cific guideline. The following terminology was adopted:
Should be: based on systematic review/meta-analysis or trials in
young FH patients.
May be: based on clinical or observational data in young FH
patients.
Not considered on the basis of available evidence.
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interpretationofavailabledata, all suggestedrevisions for thisdocument
and all members approved the final document before submission.
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